Propofol increases µ-opioid receptor expression in SH-SY5Y human neuroblastoma cells

Li,Zuojun; Pei,Qi; Cao,Lijun; Xu,Linyong; Zhang,Bikui; Liu,Shikun

doi:10.3892/mmr.2012.1073

Propofol increases µ-opioid receptor expression in SH-SY5Y human neuroblastoma cells

Authors:
- Zuojun Li
- Qi Pei
- Lijun Cao
- Linyong Xu
- Bikui Zhang
- Shikun Liu
View Affiliations

Affiliations: Department of Pharmacy, Third Xiangya Hospital, Central South University, Changsha, P.R. China, Department of Anesthesiology, Second Xiangya Hospital, Central South University, Changsha, P.R. China, Xiangya School of Medicine, Central South University, Changsha, P.R. China
Published online on: September 10, 2012 https://doi.org/10.3892/mmr.2012.1073
Pages: 1333-1336

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to explore the effect of propofol, a intravenous sedative-hypnotic agent used widely in inducing and maintaining anesthesia, on µ-opioid receptor (MOR) expression in a human neuronal cell line. SH-SY5Y human neuroblastoma cells were treated with various concentrations of propofol (1, 5, 10 or 20 µM) for different lengths of time (6, 12 or 24 h). Real-time quantitative RT-PCR showed that at a concentration range of 1-10 µM, propofol increased MOR mRNA levels in a statistically significant dose- and time-dependent manner within 12 h of treatment. Western blot analyses demonstrated that propofol treatment for 12 h dose-dependently increased the MOR protein levels. In the 12-h SH-SY5Y-treated cells, propofol dose-dependently increased MOR density (Bmax) in the cell membranes. In addition, in the presence of the transcription inhibitor actinomycin D (1 mg/ml), propofol (10 µM) had no significant effect on the MOR mRNA levels over time. The results suggested that propofol dose- and time-dependently enhances MOR expression in SH-SY5Y human neuroblastoma cells at the transcriptional level, leading to an increased density of ligand-binding MORs in the cell membranes. This study demonstrated for the first time a link between propofol and the opioid system, thereby providing new insights into propofol mechanism of action and potential for abuse.

View Figures

View References

1	Marik PE: Propofol: an immunomodulating agent. Pharmacotherapy. 25:S28–S33. 2005. View Article : Google Scholar
2	Tramèr M, Moore A and McQuay H: Propofol anaesthesia and postoperative nausea and vomiting: quantitative systematic review of randomized controlled studies. Br J Anaesth. 78:247–255. 1997.PubMed/NCBI
3	Schaer H: Propofol infusion for the maintenance of short-term anesthesia. Anaesthesist. 37:187–192. 1988.(In German).
4	Wilson C, Canning P and Caravati EM: The abuse potential of propofol. Clin Toxicol (Phila). 48:165–170. 2010. View Article : Google Scholar
5	Kotani Y, Shimazawa M, Yoshimura S, Iwama T and Hara H: The experimental and clinical pharmacology of propofol, an anesthetic agent with neuroprotective properties. CNS Neurosci Ther. 14:95–106. 2008. View Article : Google Scholar : PubMed/NCBI
6	Kalyuzhny AE, Dooyema J and Wessendorf MW: Opioid- and GABA(A)-receptors are co-expressed by neurons in rat brain. Neuroreport. 11:2625–2628. 2000. View Article : Google Scholar : PubMed/NCBI
7	Zhang G, Chen W and Marvizón JC: Src family kinases mediate the inhibition of substance P release in the rat spinal cord by μ-opioid receptors and GABA(B) receptors, but not α2 adrenergic receptors. Eur J Neurosci. 32:963–973. 2010.PubMed/NCBI
8	Mao J: NMDA and opioid receptors: their interactions in antinociception, tolerance and neuroplasticity. Brain Res Brain Res Rev. 30:289–304. 1999. View Article : Google Scholar : PubMed/NCBI
9	Al-Hasani R and Bruchas MR: Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology. 115:1363–1381. 2011.PubMed/NCBI
10	Mayer P and Höllt V: Pharmacogenetics of opioid receptors and addiction. Pharmacogenet Genomics. 16:1–7. 2006. View Article : Google Scholar : PubMed/NCBI
11	Di Toro R, Baiula M and Spampinato S: Expression of the repressor element-1 silencing transcription factor (REST) is influenced by insulin-like growth factor-I in differentiating human neuroblastoma cells. Eur J Neurosci. 21:46–58. 2005.PubMed/NCBI
12	Zhang Y, Wang D, Johnson AD, Papp AC and Sadée W: Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem. 280:32618–32624. 2005. View Article : Google Scholar : PubMed/NCBI
13	Munson PJ and Rodbard D: Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 107:220–239. 1980. View Article : Google Scholar : PubMed/NCBI
14	Guarino G and Spampinato S: Nandrolone decreases mu opioid receptor expression in SH-SY5Y human neuroblastoma cells. Neuroreport. 19:1131–1135. 2008. View Article : Google Scholar : PubMed/NCBI
15	Petroni D, Tsai J, Mondal D and George W: Attenuation of low dose methylmercury and glutamate induced-cytotoxicity and tau phosphorylation by an N-methyl-D-aspartate antagonist in human neuroblastoma (SHSY5Y) cells. Environ Toxicol. Oct 5–2011.(Epub ahead of print). View Article : Google Scholar
16	Massone S, Vassallo I, Fiorino G, et al: 17A, a novel non-coding RNA, regulates GABA B alternative splicing and signaling in response to inflammatory stimuli and in Alzheimer disease. Neurobiol Dis. 41:308–317. 2011. View Article : Google Scholar : PubMed/NCBI
17	Gianoulakis C: Endogenous opioids and addiction to alcohol and other drugs of abuse. Curr Top Med Chem. 4:39–50. 2004. View Article : Google Scholar : PubMed/NCBI
18	López-Moreno JA, López-Jiménez A, Gorriti MA and de Fonseca FR: Functional interactions between endogenous cannabinoid and opioid systems: focus on alcohol, genetics and drug-addicted behaviors. Curr Drug Targets. 11:406–428. 2010.PubMed/NCBI
19	Berrendero F, Robledo P, Trigo JM, Martín-García E and Maldonado R: Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system. Neurosci Biobehav Rev. 35:220–231. 2010. View Article : Google Scholar : PubMed/NCBI
20	Ray LA, Barr CS, Blendy JA, Oslin D, Goldman D and Anton RF: The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review. Alcohol Clin Exp Res. 36:385–394. 2012. View Article : Google Scholar : PubMed/NCBI
21	Carrasco G, Molina R, Costa J, Soler JM and Cabré L: Propofol vs midazolam in short-, medium-, and long-term sedation of critically ill patients: a cost-benefit analysis. Chest. 103:557–564. 1993. View Article : Google Scholar : PubMed/NCBI
22	Miller LJ and Wiles-Pfeifler R: Propofol for the long-term sedation of a critically ill patient. Am J Crit Care. 7:73–76. 1998.PubMed/NCBI
23	Boyle WA, Shear JM, White PF and Schuller D: Long-term sedative infusion in the intensive care unit: propofol vs midazolam. J Drug Dev. 4(Suppl): S43–S45. 1991.
24	Cammarano WB, Pittet JF, Weitz S, Schlobohm RM and Marks JD: Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Crit Care Med. 26:676–684. 1998. View Article : Google Scholar : PubMed/NCBI
25	Au J, Walker S and Scott DHT: Withdrawal syndrome after propofol infusion. Anaesthesia. 45:741–742. 1990. View Article : Google Scholar : PubMed/NCBI
26	McAuliffe PF, Gold MS, Bajpai L, et al: Second-hand exposure to aerosolized intravenous anesthetics propofol and fentanyl may cause sensitization and subsequent opiate addiction among anesthesiologists and surgeons. Med Hypotheses. 66:874–882. 2006. View Article : Google Scholar
27	Kashiwagi M, Osaka Y, Onimaru H and Takeda J: Optical imaging of propofol-induced central respiratory depression in medulla-spinal cord preparations from newborn rats. Clin Exp Pharmacol Physiol. Jan 19–2011.(Epub ahead of print). View Article : Google Scholar